Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HCN4 | Q9Y3Q4 | 9/20 | 0.33 |
| ▸ | HCN1 | O60741 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HCN3 | Q9P1Z3 | 1/20 | 0.31 |
| ▸ | HCN2 | Q9UL51 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16036398 | 0.99 | TP53 (0.33) | TP53HCN4HCN1ALDH1A1TSHR | |
| SCHEMBL30926497 | 0.89 | STK17B (0.37) | TP53HCN4HCN1 | |
| SCHEMBL16076736 | 0.89 | STK17B (0.37) | TP53HCN4HCN1 | |
| SCHEMBL20959593 | 0.88 | WNT1 (0.34) | — | |
| SCHEMBL20959598 | 0.88 | WNT1 (0.34) | — | |
| SCHEMBL29620330 | 0.88 | STK17B (0.38) | — | |
| SCHEMBL4549858 | 0.88 | STK17B (0.38) | — | |
| SCHEMBL20913367 | 0.86 | TP53 (0.35) | TP53HCN4ALDH1A1MC4RLMNA | |
| SCHEMBL24052556 | 0.86 | — | — | |
| SCHEMBL25857099 | 0.86 | HCAR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | G1 THERAPEUTICS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | TP53 25/4885HCN4 4659/4885HCN1 4717/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | TP53 25/4885HCN4 4659/4885HCN1 4717/4885 |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | TYMS, TYMP, DPYD | TP53 25/4885HCN4 4659/4885HCN1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.